Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05157763 · ClinicalTrials.gov registry record · Phase 1

A Study to Evaluate the Safety and Efficacy of EscharEx (EX-02) in the Treatment of Basal Cell Carcinoma

A Phase 1 study of Superficial Basal Cell Carcinoma and Nodular Basal Cell Carcinoma, sponsored by MediWound.

Recruiting
Registry status
Phase 1
Development phase
32
Enrollment target
3
Study locations

NCT05157763 is a Phase 1 study of Superficial Basal Cell Carcinoma and Nodular Basal Cell Carcinoma that is actively recruiting participants, run by MediWound. The registered enrollment target is 32 participants, below the 110-participant average among 5 other Superficial Basal Cell Carcinoma trials with a reported enrollment target (71% lower). The trial reports 3 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05157763, a Phase 1 study of Superficial Basal Cell Carcinoma and Nodular Basal Cell Carcinoma, is actively recruiting participants, sponsored by MediWound.

RECRUITING
Registry status
Phase 1
Development phase
32 participants
Enrollment target
3
Study locations

Study Summary

This study will be a multicenter, prospective, open label, one-arm study intended to assess the Safety and Efficacy of EscharEx (EX-02) in the treatment of Basal Cell Carcinoma. In patients with one primary superficial or nodular basal cell carcinoma lesion with a diameter of 5-10mm (Histologically confirmed BCC) located on the trunk or upper extremities (not including the hands), with well-defined borders and no previous radiation therapy.

Conditions Studied

Superficial Basal Cell Carcinoma Nodular Basal Cell Carcinoma

Interventions

  • DRUG EscharEx 5% (EX-02 formulation)

Study Locations (3)

Florida

  • Center for Clinical and Cosmetic Research - Aventura
  • Moore Clinical Research, Inc. - Brandon

Texas

  • Center for Clinical Studies, LTD. LLP - Webster

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2021-06-30
Est. Completion 2022-06
Phase Phase 1

Sponsor

MediWound

7 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05157763

The ClinicalTrials.gov registry entry for NCT05157763 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 110-participant average among 5 other Superficial Basal Cell Carcinoma trials with a reported enrollment target (71% lower). The listed sponsor is MediWound, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Superficial Basal Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which EscharEx 5% (EX-02 formulation) is the first listed.

NCT05157763 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Florida, Texas.

Frequently Asked Questions

What is clinical trial NCT05157763 about?

NCT05157763 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of EscharEx (EX-02) in the Treatment of Basal Cell Carcinoma". This study will be a multicenter, prospective, open label, one-arm study intended to assess the Safety and Efficacy of EscharEx (EX-02) in the treatment of Basal Cell Carcinoma. In patients with one primary superficial or nodular basal cell carcinoma lesion with a diameter of 5-10mm (Histologically...

What is the current status of trial NCT05157763?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2021-06-30. Estimated completion is 2022-06.

What conditions does trial NCT05157763 study?

This clinical trial studies the following conditions: Superficial Basal Cell Carcinoma, Nodular Basal Cell Carcinoma.

What interventions are being tested in trial NCT05157763?

The interventions under investigation include: EscharEx 5% (EX-02 formulation) (DRUG).

Who is sponsoring clinical trial NCT05157763?

This trial is sponsored by MediWound, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05157763 being conducted?

This trial has 3 study locations across Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Superficial Basal Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Superficial Basal Cell Carcinoma

All registered trials for this condition

Nodular Basal Cell Carcinoma

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.